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Abstract
B-1 lymphocytes exhibit unique phenotypic, ontogenic, and functional characteristics that differ 
from the conventional B-2 cells. B-1 cells spontaneously secrete germline-like, repertoire skewed 
polyreactive natural antibody, which acts as a first line of defense by neutralizing a wide range of 
pathogens before launching of the adaptive immune response. Immunomodulatory molecules, 
such as interleukin-10 (IL-10), adenosine, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), IL-3, and IL-35 are also produced by B-1 cells in the presence or absence of 
stimulation, which regulate acute and chronic inflammatory diseases. Considerable progress has 
been made during the past three decades since the discovery of B-1 cells, which has not only 
improved our understanding of their phenotypic and ontogenic uniqueness but also their role in 
various inflammatory diseases including influenza, pneumonia, sepsis, atherosclerosis, 
inflammatory bowel disease (IBD), autoimmunity, obesity and diabetes mellitus. Recent 
identification of human B-1 cells widens the scope of this field, leading to novel innovations that 
can be implemented from bench to bedside. Among the vast number of studies on B-1 cells, we 
have carried out a literature review highlighting current trends in the study of B-1 cell involvement 
during inflammation, which may result in a paradigm shift towards sustainable therapeutics in 
various inflammatory diseases.
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Introduction
Inflammation accompanies the body’s immune response. An inadequate response may lead 
to a lack of clearance of invading organisms, whereas a hyper immune response could cause 
tissue damage, and even death of the host [1]. Immediately after the host encounters a 
pathogen, the innate immune system consisting of neutrophils, macrophages, dendritic cells, 
natural killer (NK) cells, and circulating proteins becomes active to confer protection. In 
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contrast, the adaptive immune system, which includes antibodies (Abs) produced by B-
lymphocytes and T-cell-mediated immunity becomes responsive at a later time point [1]. 
Although a large proportion of mature B-cells are primarily responsible for mediating 
adaptive immunity via Ab production, B-cells also contribute to innate immunity and exhibit 
critical immunoregulatory roles. For the purpose of this review, we will focus on B-1a cells 
unless otherwise mentioned.
In mice, mature B-cells consist of three major subsets: i) follicular B-cells, also known as 
B-2 cells, located in lymphoid follicles, ii) marginal zone (MZ) B-cells localized proximal to 
the marginal sinus of the spleen, and iii) B-1 cells most abundant in peritoneal and pleural 
cavities [5, 6]. B-2 cells mount Ab responses in a T-cell-dependent manner, while both MZ 
B-cells and B-1 cells generate T-cell-independent responses [6]. Depending on the presence 
or absence of surface CD5, a pan T-cell marker, B-1 cells can be further subdivided into 
B-1a (CD5+) and B-1b (CD5−) populations [7]. A growing body of evidence supports 
considering B-1 cells to be a part of the innate immune system, whereas B-2 cells function 
primarily in adaptive immune responses [6, 8].
Murine B-1a cells spontaneously secrete and maintain steady-state levels of natural Abs of 
the immunoglobulin M (IgM) isotype in naïve, non-immunized, and antigen-free mice 
[reviewed in 9]. B-1a cell-derived natural Abs are found to counteract a wide range of viral 
and bacterial infections [10]. Recently, a specific role for B-1b cells in generating long 
lasting immunity to the relapsing fever bacterium B. hermsii has also been demonstrated 
[11]. This is consistent with other evidence that to combat pathogens B-1a cells secrete 
natural Abs that protect against infection or lower bacterial burden if infection is established; 
whereas, B-1b cells secrete induced antibody needed to clear certain bacteria and permit 
survival [12, 13]. The natural Abs secreted from B-1a cells not only neutralize invading 
pathogens but also recognize and clear dying cells leading to suppression of uncontrolled 
inflammation and autoimmunity [9].
Soon after the discovery of B-1 cells in mice [5], a number of studies demonstrated their role 
in various inflammatory diseases. Our current review encompasses the latest trends of B-1 
cell pathobiology by revisiting its immunomodulatory functions in terms of natural Ab 
secretion, antigen presentation, phagocytosis, T-cell polarization, and immune suppression 
in order to help define the therapeutic potential of B-1 cells during inflammation.
B-1 cells: A brief overview
Phenotype and localization
B-1 cells comprise a minor portion of the total B-cells in mice and display unique features in 
terms of their surface phenotype, localization, ontogenesis, and function [5, 7, 8, 12, 14–16]. 
The cell surface phenotype of murine B-1 cells is CD45R(B220)lo, surface IgM (sIgM)hi, 
sIgDlo, CD23lo/−, CD19hi and CD43+, and can be either CD5+ (B-1a) or CD5− (B-1b) [7, 
17, 18]. B-1a cells are predominantly localized in the peritoneal cavity, which accounts for a 
major portion of the total B-cells of this compartment. B-1a cells are also found in spleen, 
pleural cavity, and bone marrow, but are barely detectable in the blood and lymph nodes [5, 
17, 19, 20]. Most of the B-1a cells in the peritoneal and pleural cavities express CD11b, a 
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macrophage/granulocyte marker; however, the majority of the B-1a cells in spleen do not 
express this marker [15, 17].
Ontogeny and development
B-1a cells represent a distinct developmental lineage derived from a unique progenitor 
found in the fetal liver as well as in fetal and adult bone marrow [21]. The discovery of a 
B-1 cell specific progenitor resolved the long lasting origin debate on lineage versus 
differentiation concepts [reviewed in 22, 23]. Transfer of the B-1 cell progenitor 
(Lineage−(Lin−)B220lo/−CD19+) into immunodeficient recipients efficiently reconstituted 
B-1a and B-1b cells [21]. B-1 cell progenitors do not express syndecan-1 (CD138) or major 
histocompatibility complex (MHC) class II Ags [24]. B-1 cell progenitors first appear in the 
fetal liver around day-11 of gestation, at which time no CD45R+ B-2 progenitor cells are 
observed. Similarly, no CD45R+ cells are observed in fetal bone marrow from embryonic 
day-15, while the CD45R−/loCD19+ population is well detected [21].
The development of B-1 cells depends on IL-7Rα and Flt-3 ligand and is negatively 
regulated by Bruton’s tyrosine kinase (Btk) [25, 26]. Recently, it has been shown B-1a cells 
can also be generated by adult bone marrow [27, 28] and B-1 cell specific progenitors are 
found in adult bone marrow [21]. However, the extent to which input from adult bone 
marrow into the adult B-1a cell pool occurs is still being investigated. In adulthood, the B-1a 
cell pool is primarily maintained by self-renewal, in which mature, surface Ig-bearing B-1 
cells give rise to their own progeny [25]. Circulating B-2 B-cells by contrast generally lack 
the ability to self-renew and are instead replenished by proliferative cells in the bone 
marrow [25, 26]. The exclusive ability of B-1a cells to self-renew is supported by the 
finding that these cells constitutively phosphorylate activated signal transducer and activator 
of transcription 3 (STAT3), which may play a key role in positively regulating cyclin D2 
expression that contributes to the proliferation of these cells [8, 25, 29]. The expansion of 
B-1a cells has been shown to be controlled at least in part by Siglec-G, which is a cell-
inhibiting receptor that inhibits calcium signaling and nuclear factor-κB (NF-κB) activation 
[30]. In addition to Siglec-G, CD22, another co-inhibitory receptor, has also been shown to 
inhibit the proliferation of B-1 cells [31]. All together these findings demonstrate B-1a cells 
appear early in the life as a developmentally separate and distinct lineage.
B-1 cell function
The main function of B-1a cells in the innate immune system is spontaneous secretion of 
natural Abs, thereby maintaining resting immunoglobulin levels in the body without any 
stimulus or immunization [9]. Natural Abs form a pre-existing shield against infection 
providing protection during the period of time required for germinal center formation and 
production of adaptive Abs. It has been estimated that 80–90% of resting serum IgM, and 
50% of serum IgA is derived from B-1a cells [reviewed in 32]. Natural IgM that 
accumulates in the serum is produced by B-1 cells residing in the spleen and bone marrow 
[9, 33]. It has been shown that in animals treated with endotoxin, peritoneal B-1a cells 
migrate to the spleen where they secrete higher amounts of Abs [34, 35]. The natural Abs 
produced by B-1a cells differ from B-2 cell adaptive Abs in that they display little or no 
somatic hypermutation and minimal N-region addition, thus reflecting germline sequences 
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[33, 36]. Murine B-1a cell natural Abs are characteristically repertoire skewed, low affinity, 
and polyreactive. B-1a cell-derived natural Abs are able to recognize phosphorylcholine 
(PC), an invariant constituent of Gram positive microbial membranes such as the S. 
pneumonia bacterial cell wall, as well as membranes of other bacterial pathogens, apoptotic 
cell membranes, and oxidized lipids [9, 32]. In addition, natural Abs produced by B-1a cells 
recognize phosphatidylcholine (PtC), a key constituent of senescent red blood cell 
membranes [37]. Interaction of such natural Abs with an infectious agent can act either by 
direct inhibition, complement activation, or opsonization leading to phagocytosis and/or Ab-
dependent cell-mediated cytotoxicity [9, 32]. Natural Abs from B-1a cells are often 
autoreactive and help eliminate dead cells and their debris [38]. In so doing, potentially 
noxious molecules are removed before tissue injury can occur as a result of uncontrolled 
immune cell activation.
Apart from natural IgM, B-1a cells also spontaneously secrete IL-10 and, after stimulation 
with lipopolysaccharides (LPS), secrete GM-CSF and IL-3 [2, 3]. In addition, B-1a cells are 
efficient antigen presenting cells, providing effective signaling to T-cells via co-stimulatory 
molecules CD80/CD86, which are constitutively expressed on B-1a cells [9, 32, 39]. 
Furthermore, B-1a cells are able to induce T-cell proliferation and help induce CD4 T-cell 
differentiation to pro-inflammatory Th17 cells [40].
B-1-related cells and subsets in innate immunity
B-1a cells are part of the innate immune system, as noted above. Some functions of B-1a 
cells are segregated to a greater or lesser extent within particular subsets of B-1a cells 
defined by phenotypic markers, such as PD-L2, CD73 and PC-1. In addition, several other B 
cell subsets manifest activities that overlap with B-1a cells, including B10 cells, Breg cells 
and IRA B cells.
Regulatory B (Breg) cells/B10-cells
In the early 90s it was reported that mouse peritoneal CD5+ B-1a cells are the major source 
of IL-10, especially in the absence of stimulation, which raised the possibility of these cells 
having immunoregulatory properties [45]. The term ‘regulatory B-cells or Breg cells’ was 
coined in 2006 representing a specific subset of B-cells with immunoregulatory functions 
[46]. This Breg cell subset has more recently been labeled B10 cells. B10 cells are able to 
downregulate innate immune responses [47]. Currently, there are no phenotypic, 
transcription factors, or lineage markers that are unique to B10 cells, although the majority 
appear to correspond to B-1 cells. Therefore, B10 cells in mice and humans are functionally 
defined and enumerated by their competence to express measurable IL-10 following ex vivo 
stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin [2, 48]. B10 cells 
are predominantly found within the spleen and peritoneal cavity and are also present in 
small numbers within blood, lymph nodes, Peyer’s patches, and intestinal tissues [2, 48, 49]. 
The generalized ex vivo phenotype of B10 cells from untreated mice is 
IgMhiIgDloCD1dhiCD5+CD19hiCD23loB220hi, with <10% co-expressing IgG or IgA [2, 48, 
50].
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Innate response activator B-cells
B-cells have been shown to produce several cytokines and growth factors both in vitro and 
in vivo. Recently, Rauch et al. identified a novel B-cell population which expresses GM-
CSF upon LPS stimulation via the toll-like receptor-4 (TLR-4) pathway [51]. These cells 
comprise 1–4% of the total B-cell population in spleen after stimulation and are termed 
innate response activator (IRA) B-cells [51]. In another study, Weber et al demonstrated the 
ability of IRA B-cells to produce IL-3 if stimulated with LPS, which might play a critical 
role in emergency myelopoesis and acute inflammation [52]. Like B-1a cells, IRA B-cells 
are also capable of producing an adequate amount of IgM when stimulated with LPS. The 
surface phenotype of these cells was identified as 
CD19+B220+IgM+MHCII+CD5+CD43+CD93+CD138+VLA4+CD284hiIgD+CD23+ CD21lo 
but negative for CD11b, CD3, Ly-6G, Ly-6C, NK1.1, CD49b, Ter119, CD4, CD8, CD11c 
[51]. After performing adoptive fate mapping and parabiosis experiments using mice lacking 
B-cells and several innate signaling molecules, IRA B-cells were shown to be derived from 
peritoneal B-1a B-cells that relocated to the spleen after recognizing LPS with TLR-4 [51]. 
Transcriptome analysis of IRA B-cells and comparison to other B-cell subsets revealed that 
IRA B-cells are mainly located in serosal sites, have self-renewal ability, and appear early 
during embryonic life [51].
PD-L2-expressing B-1a cells
Interaction of the programmed death-1 receptor (PD-1) with its ligand programmed death-
ligand 1 (PD-L1) downmodulates lymphocyte activity, implying a role for PD-1 in 
regulating autoimmunity as well as immune responses to viral and parasitic infections [53, 
54]. Like T-cells and myeloid cells, B-cells also express PD-1, engagement of which by its 
ligand(s) negatively regulates B-cell activity [55]. In studying the PD-1 pathway in B-1a 
cell-mediated immunity, Zhong et al. found approximately 50–70% of resting peritoneal 
B-1a cells express PD-L2 (CD273, B7-DC), a second PD-1 ligand, which was not present or 
inducible on conventional B-2 cells [39]. This extended the range of PD-L2 expression and 
showed that it is constitutively expressed in B-cells unlike inducible expression in other cell 
types. Although PD-L2+ and PD-L2” B-1a cells are similar in proliferative responses and 
spontaneous immunoglobulin secretion, PD-L2+ B-1a cells are highly enriched for 
expression of VH11 and VH12 genes and represent the bulk of PtC-binding B-1 cells [39, 
56]. Moreover, PD-L2+ B-1a cells are highly enriched for autoreactive specificities. These 
findings show B-1 cells identified by PD-L2 express a specific repertoire.
CD73-expressing B-1a cells
In a recent study, a novel subset of B-1a cells expressing CD73 as well as CD39, two 
ectoenzymes that together catalyze the extracellular dephosphorylation of adenine 
nucleotides to adenosine, has been identified and shown to play an immunomodulatory role 
during inflammation [57]. Approximately 30–50% of total B-1 cells express high levels of 
CD73, whereas only a very minor portion of conventional B-2 cells express very low levels 
of CD73 [57]. Although extracellular adenosine triphosphate (ATP) is known to play a 
proinflammatory role, its dephosphorylated form adenosine is immunosuppressive [58]. 
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Therefore, regulating the balance of extracellular ATP and adenosine, controlled at least in 
part by CD73+ B-1a cells, is important in maintaining immune homeostasis.
PC1-expressing B-1a cells
The two classic functions of B-1a cells, i) innate-like and ii) immunoregulatory can be 
segregated between two unique subsets based on the expression of plasma cell alloantigen 1 
(PC1), also known as ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), an 
enzyme involved primarily in the hydrolysis of ATP at the cell surface [59]. These subsets, 
designated B-1a.PC1lo and B-1a.PC1hi, express distinct IgH repertoires and contribute to 
varied levels of serum and mucosal natural Abs [59]. Adoptively transferred PC1lo cells 
secreted significantly higher amount of circulating natural IgM and intestinal IgA than PC1hi 
cells [59]. In contrast, the PC1hi cells produced more IL-10 than PC1lo cells when stimulated 
with LPS and PMA and were able to regulate Th1 cell differentiation. Furthermore, PC1lo 
cells generated antigen-specific IgM responses to pneumococcal polysaccharide antigens, 
whereas PC1hi cells did not. Developmentally PC1lo cells arise from an early period of B-1a 
progenitors in fetal life, whereas PC1hi cells are generated at a later time after birth [59]. 
Therefore, identification of B-1a.PC1lo and B-1a.PC1hi cells extends our understanding of 
innate immune and immunoregulatory functions mediated by B-1a cells.
Human B-1 cells
The presence of the CD5 antigen on B-cells generating autoantibodies in rheumatoid 
arthritis patients was first considered to be the identifying marker of human B-1 cells [60, 
61]. However, CD5 is also variably present on cells of several different human B-cell 
populations, including activated, transitional, and pre-naive B-cells, which raised doubts 
about the phenotypic designation of human B-1 cells in terms of the CD5 antigen [62–64]. 
As a result, confusion regarding the very existence of B-1 or B-1-like cells in the human 
system remained. Recently, the nature of human B-1 cells was revisited by Griffin et al. who 
identified a population of B-cells in human umbilical cord and peripheral blood that 
manifested three key functional features of mouse B-1a cells [65]. These functional features 
include: i) spontaneous immunoglobulin secretion, ii) constitutive intracellular signaling, 
and iii) efficient T-cell stimulation. This population of human B-1 cells was defined as 
CD20+CD27+CD43+ with little to no surface CD69 and CD70, which are both markedly up-
regulated after activation of CD20+CD27−CD43−(naive) and CD20+CD27+CD43− 
(memory) B-cells [65, 66]. Identification of human B-1 cells will provide valuable insights 
for future studies on the role of these cells in human inflammatory diseases. A summary of 
B-1 cells, B-1 cells subsets, and related B-cells, in terms of phenotype, localization and 
function is provided in Table 1.
B-1 cells and inflammation
Inflammation refers to the host response to invading pathogens mediated by both the innate 
and adaptive arms of the immune system. B-1a cells are considered to be part of the innate 
immune system, whereas B-2 cells primarily act in the adaptive immune system [8]. Recent 
progress has been made towards elucidation of the role B-1a cells in various inflammatory 
and autoimmune diseases, which is summarized in this review.
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Influenza virus infection
Infection by influenza virus is the most common cause of human respiratory disease [67]. 
The virus spontaneously manipulates its surface proteins to generate highly variable 
epitopes, thereby making it difficult to design broadly effective vaccines against influenza 
virus. The polyreactive nature of B-1a cell-secreted natural Abs enables them to effectively 
eliminate the influenza virus infection in mice [68, 69]. According to the recent studies, 
systemic natural IgM secreted by B-1a cells is transported to mucosal surfaces through the 
poly-Ig receptor leading to protection against influenza virus infection [68, 69]. The 
importance of systemic natural IgM for protection against influenza virus has been 
documented in mice deficient in secreted IgM but normal for surface bound IgM (sIgM), 
which exhibited reduced clearance of virus and increased mortality following influenza virus 
infection [69].
Recent findings demonstrate an active role for B-1a cells which provides enhanced local 
rather than systemic defense against influenza virus [70]. This defense was shown to be 
mediated through highly localized activation of B-1a cells at lymph nodes close to the 
respiratory tract, serving as a major source of local virus-neutralizing natural IgM [70]. 
Surface expression of the CD5 antigen in B-1a cells plays an important role in regulating 
antigen driven B-cell receptor (BCR)-mediated signaling [71]. During influenza virus 
infection CD5+ B-1a cell oriented active responses are not dependent on antigen-induced 
BCR mediated proliferation but are mainly generated by their increased accumulation at the 
lungs and its related lymph nodes as a result of their translocation from serosal cavities 
where they spontenously secrete natural Abs and other immunomodulatory molecules to 
confer protection against influenza virus infection [70, 71]. B-1b or conventional B-2-cells 
on the other hand provide protection against pathogens through steps involving clonal 
expansion via BCR-mediated signals in the absence of CD5 receptor on their surfaces [11].
In some cases of infection, B-1a cell-mediated immune regulation may not be beneficial. A 
recent study revealed Xid mice deficient in B-1a cells showed better protection than normal 
animals following infection with a virulent strain of F. tularensis [72]. The poor 
performance by normal mice could be the result of B-1a cell generated IL-10 creating an 
immunosuppressive environment in which virulent strains could more easily be replicated 
rather than destroyed [72], a situation relieved in the absence of B-1a cells. Therefore, a 
finely tuned balance between B-1a mechanisms promoting immune defense and immune 
suppression is required for efficient viral clearance and recovery from infection.
S. pneumonia infection
S. pneumoniae causes acute bacterial infection especially in the lungs. Approximately 
400,000 hospitalizations from pneumococcal pneumonia infection are estimated to occur 
annually in the United States, leading to 5%-7% case-fatality, which is significantly higher 
among elderly persons [73]. With germline-like IgM and a distinctly skewed repertoire, 
B-1a cell-derived natural IgM defends against bacterial infections. In particular, anti-PC Ab 
derived from B-1a cells has been well characterized and shown to be protective against S. 
pneumoniae infection [12, 74, 75]. The importance of anti-PC and anti-pneumococcal 
capsular polysaccharide 3 (PPS3) germline-like natural Abs was shown in mice lacking 
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B-1a cells, as they were unable to survive acute infection with S. pneumoniae [12]. The 
polyreactive nature of natural IgM sometimes may not be able to effectively neutralize 
certain invading pathogens. N-addition has been shown to play a key role in antigen receptor 
diversity and Ab effectiveness to certain pathogens such as S. pneumoniae. B-1a cells also 
secrete the prototypical anti-PC antibody, T15, which has no N-addition and is completely 
germline [75, 76]. Terminal deoxytransferase (TdT) adds non templated nucleotides (N-
addition) to the V-D and D-J junctions during antibody gene recombination, increasing 
junctional diversity. Interestingly, in mice overexpressing TdT, vaccination with heat-killed 
S. pneumoniae generated an anti-PC response, but these anti-PC antibodies were not 
protective against S. pneumoniae infection [77]. This study demonstrates that excessive 
diversity generated by N-addition can be detrimental for microbial protection.
Utilizing various animal models of acute lung infection by direct intratracheal or intranasal 
delivery of LPS, E. coli or S. pneumoniae Weber, et al. showed B-1a B-cells migrate from 
the pleural space to the lung parenchyma and secrete GM-CSF and polyreactive IgM to 
confer protection against infection [78]. Such a migration model has also been proposed by 
Baumgarth et al, which suggests that body cavity B-1a cells circulate throughout the animal 
in the steady state [79]. Following infection by pathogens, innate inflammatory signals 
contribute to behavioral changes of B-1a cells in the body cavities and these responder 
populations migrate to neighboring lymphoid sites [79].
Sepsis
Sepsis is a pervasive human health concern afflicting 3 million people in the United States 
every year [80, 81]. Injury from sepsis occurs as a result of an uncontrolled inflammatory 
response [82]. The role of T- and B-cells in sepsis was first demonstrated in Rag1− / − mice, 
which were shown to succumb more readily to polymicrobial sepsis [83]. Interestingly, 
repletion of Rag1− / −mice with B-cells improves survival, demonstrating that B-cell 
function in the absence of T cell-dependent Abs is important for sepsis outcome [84]. An 
appropriate immune response is necessary to confer protection against sepsis, while the lack 
of a first line of defense may exacerbate disease pathogenesis. Intriguingly, a recent study 
demonstrated the lack of B-cells in µMT− / − mice resulted in increased mortality, similar to 
Rag1− / − mice [84]. However, T-cell-deficient TCRαβ − / − mice did not display increased 
susceptibility to sepsis-induced mortality when compared with WT mice. These findings 
suggest an essential role for B-cells and innate immune responses in sepsis.
To evaluate the role of natural IgM in the immediate response against sepsis, one of the first 
studies conducted was in mutant mice deficient in secreted (s)IgM in an acute peritonitis 
model induced by cecal ligation and puncture (CLP). This study revealed a significant 
increase in mortality in sIgM-deficient mice as compared with their WT counterparts [85]. 
This increased susceptibility was associated with a reduced level of tumor necrosis factor-α 
(TNF-α), a decreased neutrophil infiltration to clear peritoneal bacteria, and elevated levels 
of endotoxin and proinflammatory cytokines in the circulation. Conversely, resistance to 
CLP by sIgM-deficient mice was restored by reconstitution with polyclonal IgM from 
normal mouse serum [85]. The study also revealed the role of antibody specificity, inasmuch 
as administration of a monoclonal IgM specific to phosphatidylcholine (PtC) had a 
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protective effect but a monoclonal IgM specific to phosphorylcholine (PC) was not 
protective. These findings suggest a critical role of natural IgM for immediate defense 
against severe bacterial infection, and thus suggest a role for B-1a cells in responding to 
sepsis [85]. The consequences of sIgM in the murine sepsis model can be correlated with 
clinical findings where specific changes of circulating IgM occur when patients with severe 
sepsis progress into septic shock [86]. In this hospital-based study, paired comparisons at 
distinct time points over the course of sepsis showed IgM was decreased only when patients 
deteriorated from severe sepsis to septic shock. Consequently, the study also revealed that 
production of IgM by B-cells was significantly lower at all stages of sepsis compared with 
healthy controls [86]. Considering altered circulatory IgM levels as one of the fate 
determining factors for patients with sepsis, a clinical trial was conducted by administration 
of an IgM-enriched Ig preparation, known as Pentaglobin therapy, monitoring the 
progression of organ failure and septic shock in patients with severe sepsis [87]. Although 
like other clinical trials Pentaglobin therapy did not produce an improvement in any of the 
outcome measures of patients with severe sepsis, it was shown to have promising inhibitory 
effects on TNF-α production in vitro [87]. Since B-1 cells are known to contribute to the 
homeostasis of serum IgM levels, assessment of the status of B-1a cells in terms of their 
frequencies and numbers at different organs may establish a link between decreased serum 
levels of IgM and B-1a cell contents during sepsis.
The direct role of B-1 cells to temper endotoxemic inflammatory responses has been 
demonstrated recently by utilizing B-1 cell deficient Xid mice which showed increased 
mortality over WT counterparts during endotoxemia [88]. Increased levels of pro-
inflammatory cytokines, TNF-α, IL-6, and decreased levels of IL-10 were found in plasma, 
lung, and gut in Xid mice after sepsis [88]. By utilizing macrophage and B-1a cell co-culture 
experiments the investigators demonstrated that the immunomodulatory function of B-1a 
cells in sepsis could be mediated through IL-10 production [88]. However, apart from IL-10-
mediated immune regulation by B-1a cells, other relevant work suggests that the protective 
role of B-1a cells in sepsis could also be mediated through natural IgM production to 
neutralize endotoxin [89]. Reconstitution of Bruton’s tyrosine kinase (Btk)-deficient mice, 
which lack B-1a cells and have reduced levels of lgG3 and IgM, with purified normal mouse 
IgM dramatically enhances their ability to clear endotoxin [89]. The pathogenesis of sepsis 
may also arise due to uncontrolled accumulation of apoptotic cells in organs; it is therefore 
speculated that B-1 cell natural IgM could facilitate the clearance of apoptotic cells by 
phagocytes, which might aid in the amelioration of sepsis.
In response to LPS stimulation peritoneal B-1a cells proliferate, migrate to the spleen, and 
give rise to the GM-CSF+ IRA B-cell population [51]. In a murine model of sepsis, mice 
with a B-cell-restricted deficiency in GM-CSF showed increased neutrophil infiltration to 
the peritoneum [51]. However, these neutrophils had impaired phagocytic activity, and the 
mice experienced a severe cytokine storm and died. This suggests that GM-CSF-producing 
B-cells contribute to bacterial clearance by promoting neutrophil phagocytic function [51]. 
In contrast to identification of a beneficial role of IRA B-cells in sepsis, a recent report also 
revealed that these cells produce IL-3, which might degrade sepsis outcomes [52]. IL-3 
production by these cells enhanced emergency myelopoiesis leading to uncontrolled 
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cytokine storm during sepsis [52]. By contrast, although IL-3 production by IRA B-cells was 
shown to be detrimental in systemic inflammation due to accelerated emergency 
myelopoesis, a recent study revealed that improved emergency myelopoiesis could be 
beneficial for survival in neonatal sepsis [90].
Atherosclerosis
Atherosclerosis is a chronic inflammatory disorder, in which leukocytes infiltrated within 
the atherosclerotic vessels augment inflammation by increasing the expression of adhesion 
molecules, cytokines, matrix metalloproteinases, and tissue factor [91]. Inflammation during 
atherosclerosis is associated with increased levels of oxidized low-density lipoproteins 
(OxLDL) trapped in the arterial walls [92]. B-1a cells have been shown to be 
atheroprotective by their production of natural IgM that eliminate OxLDL as well as 
apoptotic and necrotic cells [93]. Healthy individuals contain basal levels of natural IgM 
which recognize OxLDL [94]. It has been reported that when atherosclerosis-prone mice 
were injected with heat-killed S. pneumonia, they generated high levels of serum anti-
OxLDL IgM that protect against atherosclerosis [95]. The direct role of natural IgM in 
atherosclerosis has also been shown by administration of natural IgM to mice with advanced 
atherosclerosis, leading to decreased severity of the disease [96]. Conversely, mice deficient 
in secretory IgM or C1q developed increased atherosclerotic lesions as compared to mice 
with normal levels of serum IgM or C1q [reviewed in 33]. Since B-1a cells maintain overall 
resting serum IgM levels, their role in protection against atherosclerosis can easily be 
understood. In support of the above statement recent literature reviews also indicate that 
B-1a cells and B-1a cell-derived natural IgM are protective against atherosclerosis [93]. 
However, in addition to natural IgM, B-1a cells may also spontaneously secrete IL-10 and 
adenosine, which inhibit inflammation produced by activated macrophages and T-cells 
present in atherosclerotic lesions [93]. Moreover, the B-1a cells can undergo in vivo 
expansion induced by self-antigens or IL-9 administration, which could serve as a potential 
therapeutic strategy to inhibit atherosclerosis [reviewed in 93].
Beyond reports that suggest natural antibodies, IL-10 and adenosine produced by B-1a and 
B10 cells may counteract inflammation that is part of atherosclerotic disease, a recent study 
demonstrated GM-CSF secreting IRA B-cells did not show any protection in atherosclerosis 
[97]. In response to a high cholesterol diet, IRA B-cell numbers in mice and humans 
increased preferentially in secondary lymphoid organs via Myd88-dependent signaling [97]. 
However, this increase may contribute to pathology inasmuch as mixed chimera mice 
lacking B-cell derived GM-CSF developed smaller lesions with fewer macrophages and 
effector T-cells. Mechanistically, IRA B-cells promote the expansion of classical dendritic 
cells, which then generate IFNγ-producing Th1 cells. This IRA B-cell-dependent Th1 
skewing manifests in an IgG1 to IgG2c isotype switch in the immunoglobulin response 
against oxidized lipoproteins. Thus, the IRA B-cells alter adaptive immune processes and 
shift leukocyte responses toward a Th1-associated milieu that aggravates atherosclerosis 
[97]. However, since these IRA B-cells still secrete natural IgM which could be beneficial, 
their role in atherosclerosis needs to be further evaluated.
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Inflammatory bowel disease
Inflammatory bowel disease (IBD), along with its two clinical subtypes, Crohn’s disease 
(CD) and ulcerative colitis (UC) are characterized by chronic and relapsing forms of severe 
gastrointestinal tract inflammation [98]. In the United States, it is currently estimated that 
about 1–1.3 million people suffer from IBD [99]. The pivotal immunoregulatory role of 
B-1a cells in protection against colitis has recently been shown by utilizing TCRα −- mice 
[100]. Under specific pathogen-free (SPF) conditions, TCRα − / − mice were found to be 
more susceptible to develop colitis than similar animals in a conventional facility [100]. Of 
note, the mice kept in the conventional facility had increased levels of natural IgM produced 
by B-1a cells to suppress colitis initiation. Conversely, B-cell-deficient Igμ (Igh6) and 
TCRα double-knockout (αμDKO) mice housed in a conventional facility continued to 
develop severe colitis, suggesting a protective role for B-1a cells. Further, when these 
αμDKO mice within the conventional facility were adoptively transferred with peritoneal 
B-1a cells isolated from TCRα −/- mice they became protected against colitis [100].
IL-10 is known to play an immunoregulatory role during colitis, as mice deficient in IL-10 
develop spontaneous colitis with many similarities to human Crohn’s disease [101]. The 
therapeutic potential of IL-10 producing regulatory B-cells or B10 cells in experimental 
colitis has been demonstrated in recent reports. Studies in CD19− / − mice, which have few, 
if any B10 cells, revealed more severe dextran sulfate sodium-induced intestinal injury than 
in WT animals [102]. Remarkably, adoptive transfer of B10 cells isolated from the spleens 
of WT mice reduced inflammation in CD19− / − mice by improving the physiological, 
histological, and immunological parameters in an IL-10-dependent manner, which may 
provide new insights and therapeutic approaches for treating ulcerative colitis [102]. 
Consistent with findings in the CD19−/- mice, G protein α inhibitory subunit 2 knockout 
(Gαi2− / −) mice, which have significantly reduced numbers of B-1a, B10, MZ, and T2 B-
cells can spontaneously develop IBD [103]. Besides the protective role of splenic B10 cells 
in colitis, a recent report characterized peritoneal cavity B10 cells in terms of spontaneous or 
inducible IL-10 production and validated their function in colitis [104]. Importantly, these 
IL-10 producing peritoneal cavity B-cells significantly reduced disease severity in 
spontaneous and induced models of colitis by regulating neutrophil infiltration, colitogenic 
CD4+ T-cell activation, and proinflammatory cytokine production during the onset of colitis, 
thereby helping to maintain homeostasis within gastrointestinal tissues and the immune 
system. A recent report regarding adenosine-producing CD73 expressing B-1a cells showed 
protection against chemically induced colitis in mice [57]. Collectively, these studies clearly 
demonstrate the potential therapeutic role of B-1a, B10 and Breg cells during intestinal 
inflammation via IgM, IL-10, and adenosine production.
Autoimmune diseases
Autoimmune diseases can affect almost any part of the body and typically have a major 
inflammatory component [105]. Different functions of B-cells, especially the secretion of 
autoantibodies, presentation of autoantigens, and secretion of inflammatory cytokines 
contribute to autoimmune diseases [106]. Considering the ability of B-1a cells to present 
antigen and skew T-cells towards Th17 differentiation, they may promote autoimmunity if 
their immunosuppressive functions as mediated by IL-10 and adenosine production become 
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dysfunctional [32, 107]. The autoreactive nature of natural IgM speeds the elimination of 
dead and dying cells and cellular debris [108]. By contrast, mice lacking natural IgM are 
prone to accelerated development of IgG autoantibodies and more severe autoimmune 
diseases, presumably because antigens and inflammation associated with apoptotic cell 
debris stimulate B-2 cell responses when not properly cleared in a timely fashion [108].
The importance of IL-10 producing regulatory B-cells for controlling experimental 
autoimmune encephalomyelitis (EAE), a Th1-mediated autoimmune disease of the central 
nervous system (CNS), has been reported recently [109, 110]. The role of B-1a cells as well 
as IL-10 producing regulatory B-cells in controlling the development of EAE has been 
examined in CD19− / − mice, which are deficient in B-1a cells [110]. The study showed that 
the greater severity of EAE in CD19− / − mice as compared with WT animals was associated 
with polarized Th1 cytokines in the inflamed CNS, causing exaggerated neuroinflammation 
[110].
Interleukin-35 belongs to the IL-12 family of cytokines and represents a potential 
therapeutic target in autoimmune, inflammatory, and infectious diseases. The 
immunosuppressive effect of IL-35 is mediated through regulatory T- and B-cells [111]. 
Wang et al. recently showed that IL-35 induced Breg cells to secrete both IL-10 and IL-35 
[4]. Injection of recombinant IL-35 or IL-35+ Breg cells into mice after induction of 
experimental autoimmune uveitis (EAU), a mouse model of autoimmune eye disease, 
resolved inflammation by suppressing effector Th1 and Th17 cell responses and inducing 
Foxp3+ Treg cells [4]. Beside the work on IL-35+ Breg cell-mediated protection against EAU, 
a supportive study by Shen et al. identified TLR-4 and CD40L co-stimulation as the main 
driver of B-cell-mediated IL-35 production in a mouse model of EAE [112]. The importance 
of IL-35+ Breg cells was demonstrated in mice lacking B-cell specific IL-35, which resulted 
in substantially worse outcomes in EAE [112]. B-cells lacking IL-35 expressed higher levels 
of co-stimulatory molecules and functioned as more potent antigen-presenting cells to T-
cells compared to IL-35 expressing B-cells, leading to stronger inflammatory T-cell 
responses [112]. Beyond IL-35, a recent study demonstrated that PD-L2+ B-1a cells may 
play a role in opposing the development of autoimmunity not only by PD-1/PD-L2-mediated 
immunosuppression but also by their specific natural IgM production [39]. Collectively 
these features reveal the importance of B-1a and Breg cells for protection against 
autoimmune diseases by secretion of imunoregulatory molecules.
Obesity and diabetes mellitus
Obesity is associated with a state of chronic, but low-grade inflammation [113]. IL-10-
secreting regulatory B-cells have an anti-inflammatory role in murine obesity [114]. 
Nishimura, et al. recently identified a distinct set of IL-10 secreting B-cells, which 
negatively regulate adipose tissue inflammation [115]. The phenotype of these IL-10 
secreting B-cells from subcutaneous and epididymal adipose tissue was identified as 
CD1dloCD5−/loCD11bloCD21/
CD35loCD23−/loCD25+CD69+CD72hiCD185−CD196+IgM+IgD+, which was phenotypically 
distinct from other IL-10 secreting B-cells isolated from spleen and peritoneal cavity 
expressing CD1dhiCD5+ [115]. It has been shown that with a deficiency of these distinct 
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IL-10 producing B-cells, infiltration of pathogenic T-cells and macrophages in adipose 
tissue of obese mice was higher than in control animals [118]. In addition, obesity is closely 
linked to other metabolic diseases such as insulin resistance and type-2 diabetes mellitus 
where regulatory B-cells play crucial roles [115]. Studies using lean mice lacking Breg cells 
exhibited insulin resistance and impaired fasting glucose clearance [118]. A recent study 
revealed that B-cells secrete a short peptide derived from proteolytic cleavage of 
adiponectin, which negatively regulates T-cell trafficking across inflammed endothelium 
[116]. Interestingly, patients with type-1 diabetes (T1D) had reduced serum levels of the 
adiponectin -derived short peptide, which implicates B-cells in controlling T1D 
pathogenesis [116]. Moreover, protection from T1D requires B-cell-derived IL-10 
production, because transfusion of activated NOD-IL-10− / − B-cells does not confer 
protection from T1D in NOD recipients [117]. Thus, evaluation of B-1a cells as well as Breg 
cells in various inflammatory diseases is likely to provide potential therapeutic possibilities 
(Fig. 1).
Conclusions and perspectives
Three decades of research on B-1 cells along with related B-cells and subsets, demonstrates 
that B-1 cells are indispensable for protection against various inflammatory diseases and for 
maintaining normal homeostasis. Although ample studies have been carried-out to 
characterize phenotypic, ontogenic, and functional profiles, additional work is still required 
to understand the complexity of how B-1 cells are involved in host pathogen interactions in 
various inflammatory diseases. The role of B-1 cells in cerebral, intestinal or hepatic 
ischemia, and other systemic inflammatory diseases is yet to be evaluated and could open 
new fields of research. Apart from natural IgM, current studies also focus on identifying 
novel molecules that are being secreted by B-1 cells to modulate the inflammatory milieu. 
Further study of novel cellular interactions involving B-1 cells and B-1 cell trafficking in 
various organs after inflammation may resolve several unanswered questions of disease 
pathogenesis. A clear dissection of B-1 cell biology will help to develop novel approaches 
for the prevention of infectious, autoimmune, and inflammatory diseases.
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Figure 1. Role of B-1 cells in inflammatory diseases
B-1 cells recognize endogenous antigens and invading pathogens through B-cell receptor 
(BCR) or toll-like receptor (TLR)-mediated pathway. Reorganization of Ag causes B-1a 
cells to migrate from the peritoneal or pleural cavities to the regional lymph nodes or spleen 
where they may become activated to IgM producing B-cells/memory B-cells. The 
polyreactive, repertoire skewed natural IgM recognize wide range of endogenous and 
exogenous Ag to eliminate from the host thus, reducing systemic inflammation. GM-CSF 
secreting IRA B-cells migrate to the spleen and lungs and confer protection against systemic 
as well as local S. pneumonia-induced inflammation. By contrast, the IRA B-cells convert 
Ly6Clo monocytes to pathogenic Ly6Chi monocytes in the spleen which then traffic to the 
atherosclerotic lesions and become atherogenic foam cells, thereby exacerbating 
atherosclerosis. Apart from B-1 and IRA B-cells, regulatory B-cells play protective roles 
against various systemic, autoimmune and inflammatory bowel disease by producing 
immunoregulatory cytokine, IL-10, and natural IgM.
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Table 1
Phenotype, location and function of B-1 cells, B-1 cell subsets, and B-1 related B-cell subsets
Cell types Phenotype Location Function References
B-1a B220loCD23−
CD5+CD19+
IgMhiIgDlo
CD43+
PerC, spleen,
pleural cavity, bone
marrow, intestine
Spontaneously secret polyreactive
natural IgM in an antigen-independent
manner that recognize pathogens,
OxLDL; Promote phagocytic
clearance of apoptotic cells; Th17 cell
differentiation
6, 8
B-1b B220loCD23−CD5−
CD19+IgMhiIgDlo
CD43+CD1dmid
PerC, spleen, lung Produce Abs after encountering T-
cell-independent antigens
11
Marginal
zone
B220+CD23−IgMhi
IgDloCD21hi
CD43−CD1dhi
Marginal sinus of
spleen, subcapsular
sinus of lymph
nodes*
Antigen presentation, elicit T-cell-
independent immune response
44
Follicular B220hiCD19+
CD23hiCD1dmid
CD21midIgMloIgDhi
Germinal centers
of spleen
Elicit T-cell-dependent responses to
protein antigens
118
IRA B IgMhiIgDloCD23lo
CD43+CD93+
VLA4hiCD19hi
CD284+GMCSF+
PerC, spleen,
serosal sites
Secret GM-CSF and regulate IgM
production via GM-CSF axis in an
autocrine manner; induce emergency
myelopoesis by IL-3 production
51, 52
Breg/B10 CD5+CD19hi
CD1d+/hiCD21+
CD23+/−CD43+/−
IgMhiIgDloIL10+
Spleen, PerC,
blood*
Regulate inflammatory responses
through IL-10 production
102
B-1a.PD-L2 B220loCD23−CD5+
CD173(B7-DC)+
IgMhiIgDlo
Spleen, PerC Repertoire skewed production of PtC-
binding VH11 and VH12 Ig which play
key role in immune defense against
bacterial infection
39
B-1a.CD73hi B220loCD23−
CD73hiCD39+
Spleen, PerC Produce adenosine in the presence of
substrate and play an
immunomodulatory role during
inflammation
57
B-1a.PC1lo/hi CD19+CD5+CD23−PC1lo/hi PerC Play innate-like or immunoregulatory
function based on natural IgM or IL-
10 production by PC1 low and high
expressing B-1a subsets, respectively
59
IL-35+ B-1 IgM+CD138hi
CD43+TACI+
CXCR4+CD1dmid
Tim1mid
Spleen Express anti-inflammatory cytokines
and regulate T-cell-mediated hyper
immunity
4, 112
CD138+
B-1a
B220loCD23−
CD5+CD138+
IgMhiIgDlo
Spleen Secrete large amounts of natural IgM
which are skewed with respect to N-
region addition, and some aspects of
VH and JH utilization
119
Human B-1 CD3−CD19+CD20+
CD27+CD43+
CD69− CD70−
Umbilical cord and
adult peripheral
blood
Spontaneous natural IgM and IL-10
secretion to regulate inflammation
65, 66
*human; PerC, peritoneal cavity; IgM, immunoglobulin M; OxLDL, oxidized low-density lipoprotein; GM-CSF, granulocyte-macrophage colony-
stimulating factor; PtC, phosphatidylcholine
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